Home Articles List Article Information
ALEXMED ePosters
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Zaki, N., Nafea, D., Moussa, M., imbaby, S., Mohungoo, S. (2023). A STUDY OF SERUM IMMUNOGLOBULIN LEVELS IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING STANDARD INDUCTION CHEMOTHERAPY. ALEXMED ePosters, 5(4), 31-32. doi: 10.21608/alexpo.2023.247032.1729
Nadia Zaki; Dalia Ahmed Nafea; Mayada Aly Moussa; salma alaa eldin imbaby; Sheik Mohammad Irfaan Mohungoo. "A STUDY OF SERUM IMMUNOGLOBULIN LEVELS IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING STANDARD INDUCTION CHEMOTHERAPY". ALEXMED ePosters, 5, 4, 2023, 31-32. doi: 10.21608/alexpo.2023.247032.1729
Zaki, N., Nafea, D., Moussa, M., imbaby, S., Mohungoo, S. (2023). 'A STUDY OF SERUM IMMUNOGLOBULIN LEVELS IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING STANDARD INDUCTION CHEMOTHERAPY', ALEXMED ePosters, 5(4), pp. 31-32. doi: 10.21608/alexpo.2023.247032.1729
Zaki, N., Nafea, D., Moussa, M., imbaby, S., Mohungoo, S. A STUDY OF SERUM IMMUNOGLOBULIN LEVELS IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING STANDARD INDUCTION CHEMOTHERAPY. ALEXMED ePosters, 2023; 5(4): 31-32. doi: 10.21608/alexpo.2023.247032.1729

A STUDY OF SERUM IMMUNOGLOBULIN LEVELS IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING STANDARD INDUCTION CHEMOTHERAPY

Article 1, Volume 5, Issue 4, December 2023, Page 31-32  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2023.247032.1729
View on SCiNiTO View on SCiNiTO
Authors
Nadia Zaki1; Dalia Ahmed Nafea2; Mayada Aly Moussa2; salma alaa eldin imbaby3; Sheik Mohammad Irfaan Mohungoo email 2
1Department of Hematology, Alexandria University
2Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Alexandria University
3Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of medicine, Alexandria university, Egypt.
Abstract
Acute myeloid leukemia (AML) is a heterogenous malignant disease caused by an impaired differentiation of hematopoietic stem cells into myeloid cells leading to accumulation of immature blast cells in the bone marrow (BM), the peripheral blood (PB) and rarely other organs. AML accounts for 80% of adult acute leukemia and is primarily a disease of older adults with an annual incidence rate of 20.1 per 100,000 population in those aged above 65 years.
Induction chemotherapy with anthracycline and cytarabine, is the mainstay for treatment of AML; all trans retinoic acid (ATRA) or arsenic trioxide (ATO) are added in Acute Promyelocytic Leukemia cases (APL). However, induction chemotherapy also induces more prolonged neutropenia in AML patients, favoring infectious complications and deaths. Immunoglobulins (Ig) are produced by B-cells in response to bacteria, viruses, fungi, parasites, cellular antigens, chemicals, and synthetic substances. Decreased serum immunoglobulin levels are associated with lower survival rate in septic patients.
Keywords
Acute myeloid leukemia (AML); IMMUNOGLOBULIN; Febrile Neutropenia
Supplementary Files
Statistics
Article View: 66